{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T20:20:56Z","timestamp":1773865256524,"version":"3.50.1"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2013,5,2]],"date-time":"2013-05-02T00:00:00Z","timestamp":1367452800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Hum Genet"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1038\/jhg.2013.37","type":"journal-article","created":{"date-parts":[[2013,5,2]],"date-time":"2013-05-02T11:10:18Z","timestamp":1367493018000},"page":"317-326","source":"Crossref","is-referenced-by-count":65,"title":["Pharmacogenomics of severe cutaneous adverse reactions and drug-induced liver injury"],"prefix":"10.1038","volume":"58","author":[{"given":"Nahoko","family":"Kaniwa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiro","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,5,2]]},"reference":[{"key":"BFjhg201337_CR1","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1001\/jama.279.15.1200","volume":"279","author":"J Lazarou","year":"1998","unstructured":"Lazarou, J., Pomeranz, B. H. & Corey, P. N. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279, 1200\u20131205 (1998).","journal-title":"JAMA"},{"key":"BFjhg201337_CR2","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/s11606-010-1518-3","volume":"26","author":"T Morimoto","year":"2011","unstructured":"Morimoto, T., Sakuma, M., Matsui, K., Kuramoto, N., Toshiro, J., Murakami, J. et al. Incidence of adverse drug events and medication errors in Japan: the JADE study. J. Gen. Intern. Med. 26, 148\u2013153 (2011).","journal-title":"J. Gen. Intern. Med."},{"key":"BFjhg201337_CR3","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1136\/bmj.316.7140.1295","volume":"316","author":"M Pirmohamed","year":"1998","unstructured":"Pirmohamed, M., Breckenridge, A. M., Kitteringham, N. R. & Park, B. K. Adverse drug reactions. BMJ 316, 1295\u20131298 (1998).","journal-title":"BMJ"},{"key":"BFjhg201337_CR4","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1001\/archderm.1993.01680220104023","volume":"129","author":"S Bastuji-Garin","year":"1993","unstructured":"Bastuji-Garin, S., Rzany, B., Stern., R. S., Shear, N. H., Naldi, L. & Roujeau, J. C. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch. Dermatol. 129, 92\u201396 (1993).","journal-title":"Arch. Dermatol."},{"key":"BFjhg201337_CR5","volume-title":"Toxic Epidermal Necrolysis - Handling Manual for Individual Severe Adverse Reactions","author":"K Hashimoto","year":"2007","unstructured":"Hashimoto, K., Iijima, M., Shiohara., T., Asahina, A., Ikezawa, Z., Nankou, H. et al. Toxic Epidermal Necrolysis - Handling Manual for Individual Severe Adverse Reactions Vol. 1 (Japan Pharmaceutical Information Center, Tokyo, 2007)."},{"key":"BFjhg201337_CR6","volume-title":"Drug Induced Hypersensitivity Syndrome\u2014Dermatology Practice 19, Insight into Skin Rash","author":"K Hashimoto","year":"2006","unstructured":"Hashimoto, K. Drug Induced Hypersensitivity Syndrome\u2014Dermatology Practice 19, Insight into Skin Rash (Bunkoudou, Tokyo, 2006)."},{"key":"BFjhg201337_CR7","first-page":"60","volume":"4613","author":"Y Saito","year":"2012","unstructured":"Saito, Y. & Sudo, C. Occurrence and causative drugs of SJS\/TEN. Jpn Med. J. 4613, 60\u201361 (2012).","journal-title":"Jpn Med. J."},{"key":"BFjhg201337_CR8","first-page":"80","volume":"19","author":"MJ Torres","year":"2009","unstructured":"Torres, M. J., Mayorga, C. & Blanca, M. Nonimmediate allergic reactions induced by drugs: pathogenesis and diagnostic tests. J. Investig. Allergol. Clin. Immunol. 19, 80\u201390 (2009).","journal-title":"J. Investig. Allergol. Clin. Immunol."},{"key":"BFjhg201337_CR9","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/428486a","volume":"428","author":"WH Chung","year":"2004","unstructured":"Chung, W. H., Hung, S. I., Hong, H. S., Hsih, M. S., Yang, L. C., Ho, H. C. et al. A marker for Stevens-Johnson syndrome. Nature 428, 486 (2004).","journal-title":"Nature"},{"key":"BFjhg201337_CR10","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1097\/01.fpc.0000199500.46842.4a","volume":"16","author":"SI Hung","year":"2006","unstructured":"Hung, S. I., Chung, W. H., Jee, S. H., Chen, W. C., Chang, Y. T., Lee, W. R. et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet. Genomics 16, 297\u2013306 (2006).","journal-title":"Pharmacogenet. Genomics"},{"key":"BFjhg201337_CR11","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1111\/j.1528-1167.2007.01022.x","volume":"48","author":"CB Man","year":"2007","unstructured":"Man, C. B., Kwan, P., Baum, L., Yu, E., Lau, K. M., Cheng, A. S. et al. Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia 48, 1015\u20131018 (2007).","journal-title":"Epilepsia"},{"key":"BFjhg201337_CR12","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/sj.tpj.6500356","volume":"6","author":"C Lonjou","year":"2006","unstructured":"Lonjou, C., Thomas, L., Borot, N., Ledger, N., de Toma, C., LeLouet, H. et al. A marker for Stevens-Johnson syndrome: ethnicity matters. Pharmacogenom. J. 6, 265\u2013268 (2006).","journal-title":"Pharmacogenom. J."},{"key":"BFjhg201337_CR13","doi-asserted-by":"publisher","first-page":"579","DOI":"10.4103\/0378-6323.57718","volume":"75","author":"TY Mehta","year":"2009","unstructured":"Mehta, T. Y., Prajapati, L. M., Mittal, B., Joshi, C. G., Sheth, J. J., Patel, D. B. et al. Association of HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians. Indian J. Dermatol. Venereol. Leprol. 75, 579\u2013582 (2009).","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"key":"BFjhg201337_CR14","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1111\/j.1528-1167.2010.02533.x","volume":"51","author":"W Tassaneeyakul","year":"2010","unstructured":"Tassaneeyakul, W., Tiamkao, S., Jantararoungtong, T., Chen, P., Lin, S. Y., Chen, W. H. et al. Association between HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population. Epilepsia 51, 926\u2013930 (2010).","journal-title":"Epilepsia"},{"key":"BFjhg201337_CR15","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.seizure.2011.02.003","volume":"20","author":"Q Wang","year":"2011","unstructured":"Wang, Q., Zhou, J. Q., Zhou, L. M., Chen, Z. Y., Fang, Z. Y., Chen, S. D. et al. Association between HLA-B*1502 allele and carbamazepine-induced severe cutaneous adverse reactions in Han people of southern China mainland. Seizure 20, 446\u2013448 (2011).","journal-title":"Seizure"},{"key":"BFjhg201337_CR16","first-page":"15","volume":"13","author":"KS Lim","year":"2008","unstructured":"Lim, K. S., Kwan, P. & Tan, C. T. Association of HLA-B*1502 allele and carbamazepine-induced severe adverse cutaneous drug reaction among Asians, a review. Neurol. Asia 13, 15\u201321 (2008).","journal-title":"Neurol. Asia"},{"key":"BFjhg201337_CR17","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2217\/pgs.09.162","volume":"11","author":"SI Hung","year":"2010","unstructured":"Hung, S. I., Chung, W. H., Liu, Z. S., Chen, C. H., Hsih, M. S., Hui, R. C. et al. Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese. Pharmacogenomics 11, 349\u2013356 (2010).","journal-title":"Pharmacogenomics"},{"key":"BFjhg201337_CR18","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1111\/j.1528-1167.2010.02766.x","volume":"51","author":"N Kaniwa","year":"2010","unstructured":"Kaniwa, N., Sait, O. Y., Aihara, M., Matsunaga, K., Tohkin, M., Kurose, K. et al. HLA-B*1511 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Epilepsia 51, 2461\u20132465 (2010).","journal-title":"Epilepsia"},{"key":"BFjhg201337_CR19","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.eplepsyres.2011.08.010","volume":"97","author":"SH Kim","year":"2011","unstructured":"Kim, S. H., Lee, K. W., Song, W. J., Kim, S. H., Jee, Y. K., Lee, S. M. et al. Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans. Epilepsy Res. 97, 190\u2013197 (2011).","journal-title":"Epilepsy Res."},{"key":"BFjhg201337_CR20","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1016\/j.jaci.2011.12.990","volume":"129","author":"CY Wei","year":"2012","unstructured":"Wei, C. Y., Chung, W. H., Huang, H. W., Chen, Y. T. & Hung, S. I. Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome. J. Allergy Clin. Immunol. 129, 1562\u20131569 (2012).","journal-title":"J. Allergy Clin. Immunol."},{"key":"BFjhg201337_CR21","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1111\/j.1346-8138.2008.00548.x","volume":"35","author":"M Kashiwagi","year":"2008","unstructured":"Kashiwagi, M., Aihara, M., Takahashi, Y., Yamazaki, E., Yamane, Y., Song, Y. et al. Human leukocyte antigen genotypes in carbamazepine-induced severe cutaneous adverse drug response in Japanese patients. J. Dermatol. 35, 683\u2013685 (2008).","journal-title":"J. Dermatol."},{"key":"BFjhg201337_CR22","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1093\/hmg\/ddq537","volume":"20","author":"T Ozeki","year":"2011","unstructured":"Ozeki, T., Mushiroda, T., Yowang, A., Takahashi, A., Kubo, M., Shirakara, Y. et al. Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum. Mol. Genet. 20, 1034\u20131041 (2011).","journal-title":"Hum. Mol. Genet."},{"key":"BFjhg201337_CR23","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1111\/j.1346-8138.2011.01457.x","volume":"39","author":"H Niihara","year":"2012","unstructured":"Niihara, H., Kakamu, T., Fujita, Y., Kaneko, S. & Morita, E. HLA-A31 strongly associates with carbamazepine-induced adverse drug reactions but not with carbamazepine-induced lymphocyte proliferation in a Japanese population. J. Dermatol. 39, 594\u2013601 (2012).","journal-title":"J. Dermatol."},{"key":"BFjhg201337_CR24","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1056\/NEJMoa1013297","volume":"364","author":"M McCormack","year":"2011","unstructured":"McCormack, M., Alfirevic, A., Bourgeois, S., Farrell, J. J., Kasperavi\u010di\u016bt\u0117, D., Carrington, M. et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N. Eng. J. Med. 364, 1134\u20131143 (2011).","journal-title":"N. Eng. J. Med."},{"key":"BFjhg201337_CR25","doi-asserted-by":"publisher","first-page":"4134","DOI":"10.1073\/pnas.0409500102","volume":"102","author":"SI Hung","year":"2005","unstructured":"Hung, S. I., Chung, W. H., Liou, L. B., Chu, C. C., Lin, M., Huang, H. P. et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc. Natl Acad. Sci. USA 102, 4134\u20134139 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFjhg201337_CR26","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1097\/FPC.0b013e328330a3b8","volume":"19","author":"W Tassaneeyakul","year":"2009","unstructured":"Tassaneeyakul, W., Jantararoungtong, T., Chen, P., Lin, P. Y., Tiamkao, S., Khunarkornsiri, U. et al. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet. Genomics 19, 704\u2013709 (2009).","journal-title":"Pharmacogenet. Genomics"},{"key":"BFjhg201337_CR27","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1159\/000102045","volume":"215","author":"T Dainichi","year":"2007","unstructured":"Dainichi, T., Uchi, H., Moroi, Y. & Furue, M. Stevens-Johnson syndrome, drug-induced hypersensitivity syndrome and toxic epidermal necrolysis caused by allopurinol in patients with a common HLA allele: what causes the diversity? Dermatology 215, 86\u201388 (2007).","journal-title":"Dermatology"},{"key":"BFjhg201337_CR28","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.2217\/14622416.9.11.1617","volume":"9","author":"N Kaniwa","year":"2008","unstructured":"Kaniwa, N., Saito, Y., Aihara, M., Matsunaga, K., Tohkin, M., Kurose, K. et al. HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics 9, 1617\u20131622 (2008).","journal-title":"Pharmacogenomics"},{"key":"BFjhg201337_CR29","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/tpj.2011.41","volume":"13","author":"M Tohkin","year":"2013","unstructured":"Tohkin, M., Kaniwa, N., Saito, Y., Sugiyama, E., Kurose, K., Nishikawa, J. et al. A whole-genome association study of major determinants for allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Pharmacogenomics J. 13, 60\u201369 (2013).","journal-title":"Pharmacogenomics J."},{"key":"BFjhg201337_CR30","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1097\/FPC.0b013e32834282b8","volume":"21","author":"HR Kang","year":"2011","unstructured":"Kang, H. R., Jee, Y. K., Kim, Y. S., Lee, C. H., Jung, J. W., Kim, S. H. et al. Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans. Pharmacogenet. Genomics 21, 303\u2013307 (2011).","journal-title":"Pharmacogenet. Genomics"},{"key":"BFjhg201337_CR31","doi-asserted-by":"publisher","first-page":"447","DOI":"10.2133\/dmpk.DMPK-11-NT-120","volume":"27","author":"K Maekawa","year":"2012","unstructured":"Maekawa, K., Nishikawa, J., Kaniwa, N., Sugiyama, E., Koizumi, T., Kurose, K. et al. Development of a rapid and inexpensive assay for detecting a surrogate genetic polymorphism of HLA-B*58:01: a partially predictive but useful biomarker for allopurinol-related Stevens-Johnson syndrome\/toxic epidermal necrolysis in Japanese. Drug Metab. Pharmacokinet 27, 447\u2013450 (2012).","journal-title":"Drug Metab. Pharmacokinet"},{"key":"BFjhg201337_CR32","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.2217\/pgs.12.89","volume":"13","author":"ZH Cao","year":"2012","unstructured":"Cao, Z. H., Wei, Z. Y., Zhu, Q. Y., Zhang, J. Y., Yang, L., Qin, S. Y. et al. HLA-B*58:01 allele is associated with augmented risk for both mild and severe cutaneous adverse reactions induced by allopurinol in Han Chinese. Pharmacogenomics 13, 1193\u20131201 (2012).","journal-title":"Pharmacogenomics"},{"key":"BFjhg201337_CR33","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S0140-6736(02)07873-X","volume":"359","author":"S Mallal","year":"2002","unstructured":"Mallal, S., Nolan, D., Witt, C., Masel, G., Martin, A. M., Moore, C. et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 359, 727\u2013732 (2002).","journal-title":"Lancet"},{"key":"BFjhg201337_CR34","doi-asserted-by":"publisher","first-page":"4180","DOI":"10.1073\/pnas.0307067101","volume":"101","author":"AM Martin","year":"2004","unstructured":"Martin, A. M., Nolan, D., Gaudieri, S., Almeida, C. A., Nolan, R., James, I. et al. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc. Natl Acad. Sci. USA 101, 4180\u20134185 (2004).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFjhg201337_CR35","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1136\/sti.2006.022335","volume":"83","author":"ST Sadiq","year":"2007","unstructured":"Sadiq, S. T. & Pakianathan, M. Uncertainties of routine HLA B*5701 testing in black African HIV cohorts in the UK. Sex. Transm. Infect. 83, 181\u2013182 (2007).","journal-title":"Sex. Transm. Infect."},{"key":"BFjhg201337_CR36","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1517\/phgs.5.2.203.27481","volume":"5","author":"AR Hughes","year":"2004","unstructured":"Hughes, A. R., Mosteller, M., Bansal, A. T., Davies, K., Haneline, S. A., Lai, E. H. et al. Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. Pharmacogenomics 5, 203\u2013211 (2004).","journal-title":"Pharmacogenomics"},{"key":"BFjhg201337_CR37","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1086\/529382","volume":"46","author":"M Saag","year":"2008","unstructured":"Saag, M., Balu, R., Phillips, E., Brachman, P., Martorell, C., Burman, W. et al. Study of hypersensitivity to abacavir and pharmacogenetic evaluation study team. High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in White and Black patients. Clin. Infect. Dis. 46, 1111\u20131118 (2008).","journal-title":"Clin. Infect. Dis."},{"key":"BFjhg201337_CR38","doi-asserted-by":"publisher","first-page":"D913","DOI":"10.1093\/nar\/gkq1128","volume":"39","author":"FF Gonzalez-Galarza","year":"2011","unstructured":"Gonzalez-Galarza, F. F., Christmas, S., Middleton, D. & Jones, A. R. Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations. Nucleic Acid Res. 39, D913\u2013D919 (2011).","journal-title":"Nucleic Acid Res."},{"key":"BFjhg201337_CR39","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1093\/jac\/dkm243","volume":"60","author":"HY Sun","year":"2007","unstructured":"Sun, H. Y., Hung, C. C., Lin, P. H., Chang, S. F., Yang, C. Y., Chang, S. Y. et al. Incidence of abacavir hypersensitivity and its relationship with HLA-B*5701 in HIV-infected patients in Taiwan. J. Antimicrob. Chemother. 60, 599\u2013604 (2007).","journal-title":"J. Antimicrob. Chemother."},{"key":"BFjhg201337_CR40","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1086\/595890","volume":"48","author":"WB Park","year":"2009","unstructured":"Park, W. B., Choe, P. G., Song, K. H., Lee, S., Jang, H. C., Jeon, J. H. et al. Should HLA-B*5701 screening be performed in every ethnic group before starting abacavir? Clin. Infect. Dis. 48, 365\u2013367 (2009).","journal-title":"Clin. Infect. Dis."},{"key":"BFjhg201337_CR41","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1097\/FPC.0b013e32831d0faf","volume":"19","author":"S Chantarangsu","year":"2009","unstructured":"Chantarangsu, S., Mushiroda, T., Mahasirimongkol, S., Kiertiburanakul, S., Sungkanuparph, S., Manosuthi, W. et al. HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients. Pharmacogenet. Genomics 19, 139\u2013146 (2009).","journal-title":"Pharmacogenet. Genomics"},{"key":"BFjhg201337_CR42","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1001\/archopht.1997.01100150552021","volume":"115","author":"S Shirato","year":"1997","unstructured":"Shirato, S., Kagaya, F., Suzuki, Y. & Joukou, S. Stevens-Johnson syndrome induced by methazolamide treatment. Arch. Ophthalmol. 115, 550\u2013553 (1997).","journal-title":"Arch. Ophthalmol."},{"key":"BFjhg201337_CR43","first-page":"613","volume":"40","author":"YJ Park","year":"1999","unstructured":"Park, Y. J., Moon, J. I. & Park, C. K. Three cases of Stevens-Johnson syndrome associated with methazolamide treatment. J. Korean. Ophthalmol. Soc. 40, 613\u2013618 (1999).","journal-title":"J. Korean. Ophthalmol. Soc."},{"key":"BFjhg201337_CR44","first-page":"561","volume":"43","author":"KH Sung","year":"2005","unstructured":"Sung, K. H., Jwong, Y., Choi, H. U. & Lee, S. K. Two cases of HLA-B59(+) Stevens-Johnson syndrome (SJS)-toxic epideremal necroylsis (TEN) associated with methazolamide treatment. Korean Dermatol. 43, 561\u2013563 (2005).","journal-title":"Korean Dermatol."},{"key":"BFjhg201337_CR45","first-page":"248","volume":"41","author":"JH Ha","year":"2003","unstructured":"Ha, J. H., Song, J. Y., Kim, H. O., Kim, C. W. & Kim, S. S. A case of Stevens-Johnson syndrome caused by acetazolamide. Korean J. Deramtol. 41, 248\u2013250 (2003).","journal-title":"Korean J. Deramtol."},{"key":"BFjhg201337_CR46","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1111\/j.1346-8138.2010.00921.x","volume":"38","author":"Y Her","year":"2011","unstructured":"Her, Y., Kil, M. S., Park, J. H., Kim, C. W. & Kim, S. S. Stevens-Johnson syndrome induced by acetazolamide. J. Dermatol. 38, 272\u2013275 (2011).","journal-title":"J. Dermatol."},{"key":"BFjhg201337_CR47","first-page":"2241","volume":"41","author":"JI Moon","year":"2000","unstructured":"Moon, J. I., Seo, J. H. & Park, C. K. Association of HLA type with Stevens-Johnson syndrome induced by methazolamide treatment. J. Korean Ophthalmol. Soc. 41, 2241\u20132246 (2000).","journal-title":"J. Korean Ophthalmol. Soc."},{"key":"BFjhg201337_CR48","doi-asserted-by":"publisher","first-page":"879","DOI":"10.2217\/pgs.10.54","volume":"11","author":"SH Kim","year":"2011","unstructured":"Kim, S. H., Kim, M., Lee, K. W., Kim, S. H., Kang, H. R., Park, H. W. et al. HLA-B*5901 is strongly associated with methazolamide-induced Stevens-Johnson syndrome\/toxic epidermal necrolysis. Pharmacogenomics 11, 879\u2013884 (2011).","journal-title":"Pharmacogenomics"},{"key":"BFjhg201337_CR49","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1289\/ehp.10325","volume":"115","author":"H Li","year":"2007","unstructured":"Li, H., Dai, Y., Huang, H., Li, L., Leng, S., Cheng, J. et al. HLA-B*1301 as a biomarker for genetic susceptibility to hypersensitivity dermatitis induced by trichloroethylene among workers in China. Environ. Health Perspect. 115, 1553\u20131556 (2007).","journal-title":"Environ. Health Perspect."},{"key":"BFjhg201337_CR50","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.ajo.2006.09.029","volume":"143","author":"M Ueta","year":"2007","unstructured":"Ueta, M., Sotozono, C., Tokunaga, K., Yabe, T. & Kinoshita, S. Strong association between HLA-A*0206 and Stevens-Johnson syndrome in the Japanese. Am. J. Ophthalmol. 143, 367\u2013368 (2007).","journal-title":"Am. J. Ophthalmol."},{"key":"BFjhg201337_CR51","first-page":"550","volume":"14","author":"M Ueta","year":"2008","unstructured":"Ueta, M., Tokunaga, K., Sotozono, C., Inatomi, T., Yabe, T., Matsushita, M. et al. HLA class I and II gene polymorphisms in Stevens-Johnson syndrome with ocular complications in Japanese. Mol. Vis. 14, 550\u2013555 (2008).","journal-title":"Mol. Vis."},{"key":"BFjhg201337_CR52","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1056\/NEJMoa0706135","volume":"358","author":"S Mallal","year":"2008","unstructured":"Mallal, S., Phillips, E., Carosi, G., Molina, J. M., Workman, C., Tomazic, J. et al. HLA-B*5701 screening for hypersensitivity to abacavir. N. Engl. J. Med. 358, 568\u2013579 (2008).","journal-title":"N. Engl. J. Med."},{"key":"BFjhg201337_CR53","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1056\/NEJMoa1009717","volume":"364","author":"P Chen","year":"2011","unstructured":"Chen, P., Lin, J. J., Lu, C. S., Ong, C. T., Hsieh, P. F., Yang, C. C. et al. Taiwan SJS Consortium. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N. Engl. J. Med. 364, 1126\u20131133 (2011).","journal-title":"N. Engl. J. Med."},{"key":"BFjhg201337_CR54","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1016\/j.jaci.2011.08.013","volume":"128","author":"TM Ko","year":"2011","unstructured":"Ko, T. M., Chung, W. H., Wei, C. Y., Shih, H. Y., Chen, J. K., Lin, C. H. et al. Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome. J. Allergy Clin. Immunol. 128, 1266\u20131276 (2011).","journal-title":"J. Allergy Clin. Immunol."},{"key":"BFjhg201337_CR55","doi-asserted-by":"publisher","first-page":"F21","DOI":"10.1097\/QAD.0b013e328355fe8f","volume":"26","author":"MA Norcross","year":"2012","unstructured":"Norcross, M. A., Luo, S., Lu, L., Boyne, M. T., Gomarteli, M., Rennels, A. D. et al. Abacavir induces loading of novel self-peptides into HLA-B*57: 01: an autoimmune model for HLA-associated drug hypersensitivity. AIDS 26, F21\u2013F29 (2012).","journal-title":"AIDS"},{"key":"BFjhg201337_CR56","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1053\/jhep.2002.34857","volume":"36","author":"C Sgro","year":"2002","unstructured":"Sgro, C., Clinard, F., Ouazir, K., Chanay, H., Allard, C., Guilleminet, C. et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 36, 451\u2013455 (2002).","journal-title":"Hepatology"},{"key":"BFjhg201337_CR57","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/0895-4356(93)90101-6","volume":"46","author":"G Danan","year":"1993","unstructured":"Danan, G. & Benichou, C. Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J. Clin. Epidemiol. 46, 1323\u20131330 (1993).","journal-title":"J. Clin. Epidemiol."},{"key":"BFjhg201337_CR58","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.hepres.2005.05.007","volume":"32","author":"H Takikawa","year":"2005","unstructured":"Takikawa, H. & Onji, M. A proposal of the diagnostic scale of drug-induced liver injury. Hepatol. Res. 32, 250\u2013251 (2005).","journal-title":"Hepatol. Res."},{"key":"BFjhg201337_CR59","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1002\/hep.20215","volume":"39","author":"RJ Andrade","year":"2004","unstructured":"Andrade, R. J., Lucena, M. I., Alonso, A., Garc\u00eda-Cortes, M., Garc\u00eda-Ruiz, E., Benitez, R. et al. HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease. Hepatology 39, 1603\u20131612 (2004).","journal-title":"Hepatology"},{"key":"BFjhg201337_CR60","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1097\/FPC.0b013e3283589a76","volume":"22","author":"TJ Urban","year":"2012","unstructured":"Urban, T. J., Shen, Y., Stolz, A., Chalasani, N., Fontana, R. J., Rochon, J. et al. Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs. Pharmacogenet. Genomics 22, 784\u2013795 (2012).","journal-title":"Pharmacogenet. Genomics"},{"key":"BFjhg201337_CR61","doi-asserted-by":"publisher","first-page":"60","DOI":"10.2133\/dmpk.DMPK-10-RV-090","volume":"26","author":"T Ikeda","year":"2011","unstructured":"Ikeda, T. Drug-induced idiosyncratic hepatotoxicity: prevention strategy developed after the troglitazone case. Drug Metab. Pharmacokinet. 26, 60\u201370 (2011).","journal-title":"Drug Metab. Pharmacokinet."},{"key":"BFjhg201337_CR62","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S0009-9236(03)00014-6","volume":"73","author":"I Watanabe","year":"2003","unstructured":"Watanabe, I., Tomita, A., Shimizu, M., Sugawara, M., Yasumo, H., Koishi, R. et al. A study to survey susceptible genetic factors responsible for troglitazone-associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus. Clin. Pharmacol. Ther. 73, 435\u2013455 (2003).","journal-title":"Clin. Pharmacol. Ther."},{"key":"BFjhg201337_CR63","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2133\/dmpk.DMPK-11-RV-111","volume":"27","author":"K Kurose","year":"2012","unstructured":"Kurose, K., Sugiyama, E. & Saito, Y. Population differences in major functional polymorphisms of pharmacokinetics\/pharmacodynamics-related genes in Eastern Asians and Europeans: implications in the clinical trials for novel drug development. Drug Metab. Pharmacokinet. 27, 9\u201354 (2012).","journal-title":"Drug Metab. Pharmacokinet."},{"key":"BFjhg201337_CR64","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1055\/s-2007-1007169","volume":"18","author":"R Whalen","year":"1998","unstructured":"Whalen, R. & Boyer, T. D. Human glutathione S-transferases. Semin. Liver Dis. 18, 345\u2013358 (1998).","journal-title":"Semin. Liver Dis."},{"key":"BFjhg201337_CR65","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1002\/hep.22370","volume":"48","author":"MI Lucena","year":"2008","unstructured":"Lucena, M. I., Andrade, R. J., Mart\u00ednez, C., Ulzurrun, E., Garc\u00eda-Mart\u00edn, E., Borraz, Y. et al. Glutathione S-transferase m1 and t1 null genotypes increase susceptibility to idiosyncratic drug-induced liver injury. Hepatology 48, 588\u2013596 (2008).","journal-title":"Hepatology"},{"key":"BFjhg201337_CR66","doi-asserted-by":"publisher","first-page":"435","DOI":"10.2217\/14622416.8.5.435","volume":"8","author":"K Ueda","year":"2007","unstructured":"Ueda, K., Ishitsu, T., Seo, T., Ueda, N., Murata, T., Hori, M. et al. Glutathione S-transferase M1 null genotype as a risk factor for carbamazepine-induced mild hepatotoxicity. Pharmacogenomics 8, 435\u2013442 (2007).","journal-title":"Pharmacogenomics"},{"key":"BFjhg201337_CR67","doi-asserted-by":"publisher","first-page":"e47769","DOI":"10.1371\/journal.pone.0047769","volume":"7","author":"Y Cai","year":"2012","unstructured":"Cai, Y., Yi, J., Zhou, C. & Shen, X. Pharmacogenetic study of drug-metabolising enzyme polymorphisms on the risk of anti-tuberculosis drug-induced liver injury: a meta-analysis. PLoS One 7, e47769 (2012).","journal-title":"PLoS One"},{"key":"BFjhg201337_CR68","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.hepres.2005.05.009","volume":"33","author":"M Mizushima","year":"2005","unstructured":"Mizushima, M., Iwata, N., Fujimoto, T. T., Ishikawa, K. & Fujimura, K. Patient characteristics in ticlopidine hydrochloride-induced liver injury: Case-control study. Hepatol. Res. 33, 234\u2013240 (2005).","journal-title":"Hepatol. Res."},{"key":"BFjhg201337_CR69","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/sj.tpj.6500442","volume":"8","author":"K Hirata","year":"2008","unstructured":"Hirata, K., Takagi, H., Yamamoto, M., Matsumoto, T., Nishiya, T., Mori, K. et al. Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case-control study. Pharmacogenomics J. 8, 29\u201333 (2008).","journal-title":"Pharmacogenomics J."},{"key":"BFjhg201337_CR70","doi-asserted-by":"publisher","first-page":"298","DOI":"10.2133\/dmpk.25.298","volume":"25","author":"N Ariyoshi","year":"2010","unstructured":"Ariyoshi, N., Iga, Y., Hirata, K., Sato, Y., Miura, G., Ishii, I. et al. Enhanced susceptibility of HLA-mediated ticlopidine-induced idiosyncratic hepatotoxicity by CYP2B6 polymorphism in Japanese. Drug Metab. Pharmacokinet. 25, 298\u2013306 (2010).","journal-title":"Drug Metab. Pharmacokinet."},{"key":"BFjhg201337_CR71","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S0016-5085(99)70404-X","volume":"117","author":"ML Hautekeete","year":"1999","unstructured":"Hautekeete, M. L., Horsmans, Y., Van Waeyenberge, C., Demanet, C., Henrion, J., Verbist, L. et al. HLA association of amoxicillin-clavulanate--induced hepatitis. Gastroenterology 117, 1181\u20131186 (1999).","journal-title":"Gastroenterology"},{"key":"BFjhg201337_CR72","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1136\/gut.47.5.717","volume":"47","author":"J O'Donohue","year":"2000","unstructured":"O'Donohue, J., Oien, K. A., Donaldson, P., Underhill, J., Clare, M., MacSween, R. N. et al. Co-amoxiclav jaundice: clinical and histological features and HLA class II association. Gut 47, 717\u2013720 (2000).","journal-title":"Gut"},{"key":"BFjhg201337_CR73","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.jhep.2010.05.033","volume":"53","author":"PT Donaldson","year":"2010","unstructured":"Donaldson, P. T., Daly, A. K., Henderson, J., Graham, J., Pirmohamed, M., Bernal, W. et al. Human leukocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury. J. Hepatol. 53, 1049\u20131053 (2010).","journal-title":"J. Hepatol."},{"key":"BFjhg201337_CR74","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1053\/j.gastro.2011.04.001","volume":"141","author":"MI Lucena","year":"2011","unstructured":"Lucena, M. I., Molokhia, M., Shen, Y., Urban, T. J., Aithal, G. P., Andrade, R. J. et al. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology 141, 338\u2013347 (2011).","journal-title":"Gastroenterology"},{"key":"BFjhg201337_CR75","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/j.1365-2125.2005.02370.x","volume":"60","author":"S Russmann","year":"2005","unstructured":"Russmann, S., Kaye, J. A., Jick, S. S. & Jick, H. Risk of cholestatic liver disease associated with flucloxacillin and flucloxacillin prescribing habits in the UK: cohort study using data from the UK General Practice Research Database. Br. J. Clin. Pharmacol. 60, 76\u201382 (2005).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"BFjhg201337_CR76","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/ng.379","volume":"41","author":"AK Daly","year":"2009","unstructured":"Daly, A. K., Donaldson, P. T., Bhatnagar, P., Shen, Y., Pe'er, I., Floratos, A. et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat. Genet. 41, 816\u2013819 (2009).","journal-title":"Nat. Genet."},{"key":"BFjhg201337_CR77","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1200\/JCO.2010.31.3197","volume":"29","author":"CF Spraggs","year":"2011","unstructured":"Spraggs, C. F., Budde, L. R., Briley, L. P., Bing, N., Cox, C. J., King, K. S. et al. HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. J. Clin. Oncol. 29, 667\u2013673 (2011).","journal-title":"J. Clin. Oncol."},{"key":"BFjhg201337_CR78","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/ng.632","volume":"42","author":"JB Singer","year":"2010","unstructured":"Singer, J. B., Lewitzky, S., Leroy, E., Yang, F., Zhao, X., Klickstein, L. et al. A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat. Genet. 42, 711\u2013714 (2010).","journal-title":"Nat. Genet."},{"key":"BFjhg201337_CR79","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1080\/10915810600683143","volume":"25","author":"J Harenberg","year":"2006","unstructured":"Harenberg, J., J\u00f6rg, I. & Weiss, C. Observations of alanine aminotransferase and aspartate aminotransferase in THRIVE studies treated orally with ximelagatran. Int. J. Toxicol. 25, 165\u2013169 (2006).","journal-title":"Int. J. Toxicol."},{"key":"BFjhg201337_CR80","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/sj.tpj.6500458","volume":"8","author":"A Kindmark","year":"2008","unstructured":"Kindmark, A., Jawaid, A., Harbron, C. G., Barratt, B. J., Bengtsson, O. F., Andersson, T. B. et al. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J. 8, 186\u2013195 (2008).","journal-title":"Pharmacogenomics J."},{"key":"BFjhg201337_CR81","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1164\/rccm.2108091","volume":"166","author":"SK Sharma","year":"2002","unstructured":"Sharma, S. K., Balamurugan, A., Saha, P. K., Pandey, R. M. & Mehra, N. K. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am. J. Respir. Crit. Care Med. 166, 916\u2013919 (2002).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"BFjhg201337_CR82","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1097\/00002030-200501030-00014","volume":"19","author":"AM Martin","year":"2005","unstructured":"Martin, A. M., Nolan, D., James, I., Cameron, P., Keller, J., Moore, C. et al. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts. AIDS 19, 97\u201399 (2005).","journal-title":"AIDS"},{"key":"BFjhg201337_CR83","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1097\/QAD.0b013e32834779df","volume":"25","author":"J Yuan","year":"2011","unstructured":"Yuan, J., Guo, S., Hall, D., Cammett, A. M., Jayadev, S., Distel, M. et al. Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent. AIDS 25, 1271\u20131280 (2011).","journal-title":"AIDS"},{"key":"BFjhg201337_CR84","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1002\/hep.23891","volume":"52","author":"JD Stewart","year":"2010","unstructured":"Stewart, J. D., Horvath, R., Baruffini, E., Ferrero, I., Bulst, S., Watkins, P. B. et al. Polymerase \u03b3 gene POLG determines the risk of sodium valproate-induced liver toxicity. Hepatology 52, 1791\u20131796 (2010).","journal-title":"Hepatology"},{"key":"BFjhg201337_CR85","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1002\/prca.200800222","volume":"3","author":"RE Jenkins","year":"2009","unstructured":"Jenkins, R. E., Meng, X., Elliott, V. L., Kitteringham, N. R., Pirmohamed, M. & Park, B. K. Characterisation of flucloxacillin and 5-hydroxymethyl flucloxacillin haptenated HSA in vitro and in vivo. Proteomics Clin. Appl. 3, 720\u2013729 (2009).","journal-title":"Proteomics Clin. Appl."},{"key":"BFjhg201337_CR86","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/hep.26077","volume":"57","author":"MM Monshi","year":"2013","unstructured":"Monshi, M. M., Faulkner, L., Gibson, A., Jenkins, R. E., Farrell, J., Earnshaw, C. J. et al. Human leukocyte antigen (HLA)-B*57:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury. Hepatology 57, 727\u2013739 (2013).","journal-title":"Hepatology"},{"key":"BFjhg201337_CR87","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1124\/jpet.111.190900","volume":"341","author":"S El-Ghaiesh","year":"2012","unstructured":"El-Ghaiesh, S., Monshi, M. M., Whitaker, P., Jenkins, R., Meng, X., Farrell, J. et al. Characterization of the antigen specificity of T-cell clones from piperacillin-hypersensitive patients with cystic fibrosis. J. Pharmacol. Exp. Ther. 341, 597\u2013610 (2012).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"BFjhg201337_CR88","doi-asserted-by":"publisher","first-page":"462","DOI":"10.3389\/fphys.2012.00462","volume":"3","author":"S Bhattacharya","year":"2012","unstructured":"Bhattacharya, S., Shoda, L. K., Zhang, Q., Woods, C. G., Howell, B. A., Siler, S. Q. et al. Modeling drug- and chemical-induced hepatotoxicity with systems biology approaches. Front. Physiol. 3, 462 (2012).","journal-title":"Front. Physiol."}],"container-title":["Journal of Human Genetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/jhg201337.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/jhg201337","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/jhg201337.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T17:31:42Z","timestamp":1684431102000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/jhg201337"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,2]]},"references-count":88,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["BFjhg201337"],"URL":"https:\/\/doi.org\/10.1038\/jhg.2013.37","relation":{},"ISSN":["1434-5161","1435-232X"],"issn-type":[{"value":"1434-5161","type":"print"},{"value":"1435-232X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,2]]}}}